Pomerantz LLP Launches Investigation Into Agios Pharmaceuticals
Following a sharp decline in share price, the Pomerantz Law Firm has initiated an investigation into potential securities fraud at Agios Pharmaceuticals. The probe centers on whether company leadership misled investors regarding the development of tebapivat, an experimental treatment for sickle cell disease that failed to meet necessary clinical benchmarks.
The scrutiny follows a July 21, 2026, announcement in which Agios disclosed the topline results from a Phase 2 trial of tebapivat. The company admitted the drug failed to demonstrate the level of differentiation required for continued development, forcing an immediate halt to the program. The market reaction was swift, with Agios shares dropping $2.70—a 6.74% decline—to close at $37.36 that same day.
Pomerantz LLP is now reviewing whether these developments, coupled with earlier corporate disclosures, constitute a breach of fiduciary duty or unlawful business practices. Investors who suffered losses are being urged to contact Danielle Peyton to discuss potential participation in a class action lawsuit.
Comments (0)
No comments yet. Be the first!